Clinical Trials Logo
  1. Home
  2. Stent Thrombosis
  3. NCT03544294

veRy Thin Stents for Patients With Left mAIn or bifurcatioN in Real Life: the RAIN a Multicenter Study — RAIN  

Stent Thrombosis Clinical Trial

Official title:
veRy Thin Stents for Patients With Left mAIn or bifurcatioN in Real Life: the RAIN a Multicenter Study

Clinical Trial Summary

For permanent coronary stents, reduction of thickness of struts have become one of the most important innovation, being related to easier manipulation, reduced risk of stent thrombosis and low rate of revascularization. Consequently the investigators performed a multicenter registry enrolling all consecutive patients treated with very thin stents for ULM or bifurcation.

Clinical Trial Description

For permanent coronary stents, reduction of thickness of struts have become one of the most important innovation, being related to easier manipulation, reduced risk of stent thrombosis and low rate of revascularization. Previous studies do not have enough power to detect potential significant difference for ULM or bifurcation lesions. Consequently the investigators performed a multicenter registry enrolling all consecutive patients treated with Biomatrix Flex, Xience Alpine, Ultimaster, Resolute Onyx and Synergy. MACE (a composite end point of death, myocardial infarction, target lesion revascularization and stent thrombosis) will be the primary end point, while its single components will be the secondary ones. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT03544294
Study type Observational [Patient Registry]
Source Azienda Ospedaliera Città della Salute e della Scienza di Torino
Contact
Status Completed
Phase
Start date June 1, 2017
Completion date May 30, 2018
View Details
See also
  Status Clinical Trial Phase
Completed NCT01205776 - EXCEL Clinical Trial N/A
Completed NCT01231035 - REsponsiveness to CLOpidogrel and Stent-related Events in Acute Coronary Syndromes (RECLOSE 2 - ACS) N/A
Completed NCT01182428 - XIENCE V: SPIRIT WOMEN Sub-study Phase 4
Completed NCT04580602 - Association Between Genetic Variant Scores and P2Y12 Inhibitor Effects
Completed NCT01205789 - EXCEL Clinical Trial (Universal Registry) N/A
Completed NCT00647504 - Prospective Clinical Observational Registry Including Consecutive Patients With In-stent Restenosis or Stent Thrombosis N/A
Active, not recruiting NCT00905008 - Long-Term Safety of Drug Eluting Stents in the "Real World" (FReIburger STent Registry) N/A
Completed NCT03118895 - Leaders Free III: BioFreedom™ Clinical Trial N/A
Completed NCT01249027 - XIENCE V Everolimus Eluting Coronary Stent System (EECSS) China: Post-Approval, Single-Arm Study
Recruiting NCT06075602 - COMPLEX Registry - A Prospective COhort Study to Describe the Management and Outcomes of Patients Presenting With compLEX and Calcified Coronary Artery Disease
Completed NCT03209843 - Post-stenting Assessment of Reendothelialization With OFDI After CTO Procedure (PERFECTO) N/A
Completed NCT01086228 - XIENCE V/PROMUS Everolimus-Eluting Stent System Post-marketing Surveillance Protocol for Japan N/A
Recruiting NCT05244629 - Copenhagen Mesenteric Stent Study - A Randomized Trial of Stent Versus Covered Stent Treatment for Chronic Mesenteric Ischemia N/A
Completed NCT00998127 - Patterns of Non-Adherence to Dual Anti-Platelet Regimen In Stented Patients N/A
Completed NCT00180479 - SPIRIT III Clinical Trial of the XIENCE V® Everolimus Eluting Coronary Stent System (EECSS) Phase 3
Recruiting NCT04988685 - SIROOP Registry - A Prospective Registry Study to Evaluate the Outcomes of Coronary Artery Disease Patients Treated With SIROlimus Or Paclitaxel Eluting Balloon Catheters
Completed NCT04734028 - PTRG-DES Consortium
Completed NCT01894152 - XIENCE PRIME Everolimus Eluting Coronary Stent System (EECSS) China Single-Arm Study
Completed NCT00496938 - XIENCE V: SPIRIT WOMEN Phase 4
Completed NCT02617290 - Assessment of Loading With the P2Y12 Inhibitor Ticagrelor or Clopidogrel to Halt Ischemic Events in Patients Undergoing Elective Coronary Stenting Phase 3